These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

126 related items for PubMed ID: 21543341

  • 1. Back to the future: mechanism-based, mutation-specific combination chemoprevention with a synthetic lethality approach.
    Meyskens FL, Gerner EW.
    Cancer Prev Res (Phila); 2011 May; 4(5):628-32. PubMed ID: 21543341
    [Abstract] [Full Text] [Related]

  • 2. Lung-cancer chemoprevention by induction of synthetic lethality in mutant KRAS premalignant cells in vitro and in vivo.
    Huang S, Ren X, Wang L, Zhang L, Wu X.
    Cancer Prev Res (Phila); 2011 May; 4(5):666-73. PubMed ID: 21543344
    [Abstract] [Full Text] [Related]

  • 3. An intermittent approach for cancer chemoprevention.
    Wu X, Lippman SM.
    Nat Rev Cancer; 2011 Nov 10; 11(12):879-85. PubMed ID: 22071977
    [Abstract] [Full Text] [Related]

  • 4. Applying synthetic lethality for the selective targeting of cancer.
    McLornan DP, List A, Mufti GJ.
    N Engl J Med; 2014 Oct 30; 371(18):1725-35. PubMed ID: 25354106
    [No Abstract] [Full Text] [Related]

  • 5. Novel multiple, monoallelic KRAS mutations at codon 12 and 13.
    Keller G, Geist B, Slotta-Huspenina J, Langer R, Nagl F, Fend F, Höfler H, Perren A.
    Int J Cancer; 2009 Dec 01; 125(11):2744-5. PubMed ID: 19521964
    [No Abstract] [Full Text] [Related]

  • 6. [Basic principles for the prevention, diagnosis and therapy of lung cancer].
    Gyula O, András B, Zoltán B, Katalin B, Attila C, Janos F, Maria G, Akos H, Lászlo K, Lászlo K, Gabor K, Gyorgy L, Judit M, Tamas MF, Zsuzsa M, Pál R, Zsolt O, János S, Zoltán S, István S, Klára S, Jozsef T, Edina T, NEFMI - Nemzeti Erőforrás Minisztérium [Department of Human Resources).
    Magy Onkol; 2012 May 01; 56(2):114-32. PubMed ID: 22724157
    [No Abstract] [Full Text] [Related]

  • 7. Isolation of a chemical inhibitor against K-Ras-induced p53 suppression through natural compound screening.
    Lee SJ, Jung YS, Lee SH, Chung HY, Park BJ.
    Int J Oncol; 2009 Jun 01; 34(6):1637-43. PubMed ID: 19424582
    [Abstract] [Full Text] [Related]

  • 8. Bexarotene plus erlotinib suppress lung carcinogenesis independent of KRAS mutations in two clinical trials and transgenic models.
    Dragnev KH, Ma T, Cyrus J, Galimberti F, Memoli V, Busch AM, Tsongalis GJ, Seltzer M, Johnstone D, Erkmen CP, Nugent W, Rigas JR, Liu X, Freemantle SJ, Kurie JM, Waxman S, Dmitrovsky E.
    Cancer Prev Res (Phila); 2011 Jun 01; 4(6):818-28. PubMed ID: 21636548
    [Abstract] [Full Text] [Related]

  • 9. Mitochondrial DNA mutations in respiratory complex-I in never-smoker lung cancer patients contribute to lung cancer progression and associated with EGFR gene mutation.
    Dasgupta S, Soudry E, Mukhopadhyay N, Shao C, Yee J, Lam S, Lam W, Zhang W, Gazdar AF, Fisher PB, Sidransky D.
    J Cell Physiol; 2012 Jun 01; 227(6):2451-60. PubMed ID: 21830212
    [Abstract] [Full Text] [Related]

  • 10. KRAS mutation analysis helps to differentiate between pulmonary metastasis from colon adenocarcinoma in situ and primary lung adenocarcinoma.
    Ortiz TM, Cohen DW, Kent MS, Jänne PA, Costa DB.
    J Thorac Oncol; 2011 Jan 01; 6(1):220-2. PubMed ID: 21178719
    [No Abstract] [Full Text] [Related]

  • 11. Evaluation of Kras gene mutation and copy number in thymic carcinomas and thymomas.
    Sasaki H, Yano M, Fujii Y.
    J Thorac Oncol; 2010 Oct 01; 5(10):1715-6. PubMed ID: 20871271
    [No Abstract] [Full Text] [Related]

  • 12. A gene expression signature of RAS pathway dependence predicts response to PI3K and RAS pathway inhibitors and expands the population of RAS pathway activated tumors.
    Loboda A, Nebozhyn M, Klinghoffer R, Frazier J, Chastain M, Arthur W, Roberts B, Zhang T, Chenard M, Haines B, Andersen J, Nagashima K, Paweletz C, Lynch B, Feldman I, Dai H, Huang P, Watters J.
    BMC Med Genomics; 2010 Jun 30; 3():26. PubMed ID: 20591134
    [Abstract] [Full Text] [Related]

  • 13. Lovastatin overcomes gefitinib resistance in human non-small cell lung cancer cells with K-Ras mutations.
    Park IH, Kim JY, Jung JI, Han JY.
    Invest New Drugs; 2010 Dec 30; 28(6):791-9. PubMed ID: 19760159
    [Abstract] [Full Text] [Related]

  • 14. PIK3CA and KRAS mutations predict for response to everolimus therapy: now that's RAD001.
    Mohseni M, Park BH.
    J Clin Invest; 2010 Aug 30; 120(8):2655-8. PubMed ID: 20664174
    [Abstract] [Full Text] [Related]

  • 15. The PI3K/AKT pathway promotes gefitinib resistance in mutant KRAS lung adenocarcinoma by a deacetylase-dependent mechanism.
    Jeannot V, Busser B, Brambilla E, Wislez M, Robin B, Cadranel J, Coll JL, Hurbin A.
    Int J Cancer; 2014 Jun 01; 134(11):2560-71. PubMed ID: 24374738
    [Abstract] [Full Text] [Related]

  • 16. Synthetic lethal genetic screens in Ras mutant cancers.
    Yu B, Luo J.
    Enzymes; 2013 Jun 01; 34 Pt. B():201-19. PubMed ID: 25034106
    [Abstract] [Full Text] [Related]

  • 17. Synthetic lethality-based therapeutics: perspectives for applications in colorectal cancer.
    Soncini D, Caffa I, Patrone F, Ballestrero A, Nencioni A.
    Curr Cancer Drug Targets; 2012 May 01; 12(4):329-38. PubMed ID: 22385509
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Targeted treatment for lung cancer could be possible due to identification of nonuniform genetic mutations.
    Jones S.
    Pharmacogenomics; 2014 May 01; 15(7):903-4. PubMed ID: 25090664
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.